- Y Diweddaraf sydd Ar Gael (Diwygiedig)
- Pwynt Penodol mewn Amser (12/02/2007)
- Gwreiddiol (Fel y’i mabwysiadwyd gan yr UE)
Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (repealed)
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
Mae unrhyw newidiadau sydd wedi cael eu gwneud yn barod gan y tîm yn ymddangos yn y cynnwys a chyfeirir atynt gydag anodiadau.Ar ôl y diwrnod ymadael bydd tair fersiwn o’r ddeddfwriaeth yma i’w gwirio at ddibenion gwahanol. Y fersiwn legislation.gov.uk yw’r fersiwn sy’n weithredol yn y Deyrnas Unedig. Y Fersiwn UE sydd ar EUR-lex ar hyn o bryd yw’r fersiwn sy’n weithredol yn yr UE h.y. efallai y bydd arnoch angen y fersiwn hon os byddwch yn gweithredu busnes yn yr UE. EUR-Lex Y fersiwn yn yr archif ar y we yw’r fersiwn swyddogol o’r ddeddfwriaeth fel yr oedd ar y diwrnod ymadael cyn cael ei chyhoeddi ar legislation.gov.uk ac unrhyw newidiadau ac effeithiau a weithredwyd yn y Deyrnas Unedig wedyn. Mae’r archif ar y we hefyd yn cynnwys cyfraith achos a ffurfiau mewn ieithoedd eraill o EUR-Lex. The EU Exit Web Archive legislation_originated_from_EU_p3
Version Superseded: 20/01/2008
Point in time view as at 12/02/2007.
There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), Division
2.
.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Closantel | Closantel | Bovine | 1 000 μg/kg | Muscle | |
3 000 μg/kg | Fat | ||||
1 000 μg/kg | Liver | ||||
3 000 μg/kg | Kidney | ||||
Ovine | 1 500 μg/kg | Muscle | |||
2 000 μg/kg | Fat | ||||
1 500 μg/kg | Liver | ||||
5 000 μg/kg | Kidney | ||||
[F2Rafoxanide | Rafoxanide | Bovine | 30 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
30 μg/kg | Fat | ||||
10 μg/kg | Liver | ||||
40 μg/kg | Kidney | ||||
Ovine | 100 μg/kg | Muscle | |||
250 μg/kg | Fat | ||||
150 μg/kg | Liver | ||||
150 μg/kg | Kidney] |
Textual Amendments
F2 Inserted by Commission Regulation (EC) No 1478/2001 of 18 July 2001 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Levamisole | Levamisole | Bovine, ovine, porcine, poultry | 10 μg/kg | Muscle | |
10 μg/kg | Fat | ||||
100 μg/kg | Liver | ||||
10 μg/kg | Kidney |
a [F3Not for use in animals producing milk for human consumption.] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
[F4Albendazole | Sum of albendazole sulphoxide, albendazole sulphone, and albendazole 2-amino sulphone, expressed as albendazole | All ruminants | 100 μg/kg | Muscle | |
100 μg/kg | Fat | ||||
1 000 μg/kg | Liver | ||||
500 μg/kg | Kidney | ||||
100 μg/kg | Milk] | ||||
[F5Albendazole oxide | Sum of albendazole oxide, albendazole sulphone and albendazole 2-aminosulphone, expressed as albendazole | Bovine, ovine | 100 μg/kg | Muscle | |
100 μg/kg | Fat | ||||
1 000 μg/kg | Liver | ||||
500 μg/kg | Kidney | ||||
100 μg/kg | Milk | ] | |||
[F4Febantel | Sum of extractable residues which may be oxidised to oxfendazole sulphone | All ruminants | 50 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
500 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
10 μg/kg | Milk | ||||
Fenbendazole | Sum of extractable residues which may be oxidised to oxfendazole sulphone | All ruminants | 50 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
500 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
10 μg/kg | Milk] | ||||
[F6Flubendazole | Sum of flubendazole and (2-amino 1H-benzimidazol-5-yl) (4fluorophenyl) methanone | Poultry, porcine | 50 μg/kg | Muscle | |
50 μg/kg | Skin + fat | ||||
400 μg/kg | Liver | ||||
300 μg/kg | Kidney | ||||
Flubendazole | Flubendazole | Poultry | 400 μg/kg | Eggs | ] |
[F7Mebendazole | Sum of mebendazole methyl (5-(1-hydroxy, 1-phenyl) methyl-1H-benzimidazol-2-yl) carbamate and (2-amino-1H-benzimidazol-5-yl) phenylmethanone, expressed as mebendazole equivalents | Ovine, caprine, equidae | 60 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
60 μg/kg | Fat | ||||
400 μg/kg | Liver | ||||
60 μg/kg | Kidney] | ||||
[F8Netobimin | Sum of albendazole oxide, albendazole sulphone and albendazole 2-aminosulphone, expressed as albendazole | [X1Bovine, ovine] | 100 μg/kg | Muscle | For oral use only |
100 μg/kg | Fat | ||||
1 000 μg/kg | Liver | ||||
500 μg/kg | Kidney | ||||
100 μg/kg | Milk] | ||||
[F4Oxfendazole | Sum of extractable residues which may be oxidised to oxfendazole sulphone | All ruminants | 50 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
500 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
10 μg/kg | Milk] | ||||
Oxibendazole | Oxibendazole | Porcine | 100 μg/kg | Muscle | |
500 μg/kg | Skin and fat | ||||
200 μg/kg | Liver | ||||
100 μg/kg | Kidney | ||||
[F4Thiabendazole | Sum of thiabendazole and 5-hydroxythiabendazole | Caprine | 100 μg/kg | Muscle | |
100 μg/kg | Fat | ||||
100 μg/kg | Liver | ||||
100 μg/kg | Kidney | ||||
100 μg/kg | Milk] | ||||
[F9Triclabendazole | Sum of extractable residues that may be oxidised to ketotriclabendazole | All ruminants a | 225 μg/kg | Muscle | |
100 μg/kg | Fat | ||||
250 μg/kg | Liver | ||||
150 μg/kg | Kidney] |
Editorial Information
X1 Substituted by Corrigendum to Commission Regulation (EC) No 807/2001 of 25 April 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Official Journal of the European Communities L 118 of 27 April 2001).
Textual Amendments
F3 Inserted by Commission Regulation (EC) No 1729/2006 of 23 November 2006 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards firocoxib and triclabendazole (Text with EEA relevance).
F4 Substituted by Commission Regulation (EC) No 1646/2004 of 20 September 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F5 Inserted by Commission Regulation (EC) No 2393/1999 of 11 November 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F6 Substituted by Commission Regulation (EC) No 1055/2006 of 12 July 2006 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards flubendazole and lasalocid (Text with EEA relevance).
F7 Inserted by Commission Regulation (EC) No 1680/2001 of 22 August 2001 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F8 Inserted by Commission Regulation (EC) No 807/2001 of 25 April 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F9 Substituted by Commission Regulation (EC) No 1729/2006 of 23 November 2006 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards firocoxib and triclabendazole (Text with EEA relevance).
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Nitroxinil | Nitroxinil | Bovine, ovine | 400 μg/kg | Muscle | |
200 μg/kg | Fat | ||||
20 μg/kg | Liver | ||||
400 μg/kg | Kidney | ||||
[F4Oxyclozanide | Oxyclozanide | All ruminants | 20 μg/kg | Muscle | |
20 μg/kg | Fat | ||||
500 μg/kg | Liver | ||||
100 μg/kg | Kidney | ||||
10 μg/kg | Milk] ] |
Textual Amendments
F10 Inserted by Commission Regulation (EC) No 997/1999 of 11 May 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Clorsulon | Clorsulon | Bovine | 35 μg/kg | Muscle | |
100 μg/kg | Liver | ||||
200 μg/kg | Kidney | ] |
Textual Amendments
F11 Inserted by Commission Regulation (EC) No 1942/1999 of 10 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Piperazine | Piperazine | Porcine | 400 μg/kg | Muscle | |
800 μg/kg | Skind and fat | ||||
2 000 μg/kg | Liver | ||||
1 000 μg/kg | Kidney | ||||
Chicken | 2 000 μg/kg | Eggs | ] |
Textual Amendments
F12 Inserted by Commission Regulation (EC) No 868/2002 of 24 May 2002 amending Annexes I and II of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Morantel | Sum of residues which may be hydrolysed to N-methyl-1,3- propanediamine and expressed as morantel equivalents | Bovine, ovine | 100 μg/kg | Muscle | |
100 μg/kg | Fat | ||||
800 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
50 μg/kg | Milk | ||||
[F14All ruminants | 100 μg/kg | Muscle | |||
100 μg/kg | Fat | ||||
800 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
50 μg/kg | Milk | ] ] |
Textual Amendments
F14 Inserted by Commission Regulation (EC) No 1356/2005 of 18 August 2005 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards oxolinic acid and morantel (Text with EEA relevance).
Textual Amendments
F13 Inserted by Commission Regulation (EC) No 1851/2004 of25 October 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits for veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
[F2Coumafos | Coumafos | Bees | 100 μg/kg | Honey | ] |
Diazinon | Diazinon | Bovine, ovine, caprine | 20 μg/kg | Milk | |
Bovine, porcine, ovine, caprine | 20 μg/kg | Muscle | |||
700 μg/kg | Fat | ||||
20 μg/kg | Liver | ||||
20 μg/kg | Kidney | ||||
[F8Phoxim | Phoxim | Ovine | 50 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
400 μg/kg | Fat | ||||
50 μg/kg | Kidney | ||||
Porcine | 20 μg/kg | Muscle | |||
700 μg/kg | Skin and fat | ||||
20 μg/kg | Liver | ||||
20 μg/kg | Kidney | ||||
[F15Chicken | 25 μg/kg | Muscle | |||
550 μg/kg | Skin + fat | ||||
50 μg/kg | Liver | ||||
30 μg/kg | Kidney | ||||
60 μg/kg | Eggs | ] ] |
Textual Amendments
F15 Inserted by Commission Regulation (EC) No 1299/2005 of 8 August 2005 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards phenoxymethylpenicillin, phoxim, norgestomet and thiamphenicol (Text with EEA relevance).
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Amitraz | Sum of amitraz and all metabolites containing the 2,4-DMA moiety, expressed as amitraz | Bovine | 200 μg/kg | Fat | |
200 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
10 μg/kg | Milk | ||||
Ovine | 400 μg/kg | Fat | |||
100 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
10 μg/kg | Milk | ||||
Porcine | 400 μg/kg | Skin and fat | |||
200 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
[F5 | Bees (honey) | 200 μg/kg | Honey | ] | |
[F16 | Caprine | 200 μg/kg | Fat | ||
100 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
10 μg/kg | Milk | ] |
Textual Amendments
F16 Inserted by Commission Regulation (EC) No 1646/2004 of 20 September 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
a [F17Further provisions in Commission Directive 98/82/EC are to be observed ( OJ L 290, 29.10.1998, p. 25 ).] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
[F8 [X1Cyhalothrin | Cyhalothrin (sum of isomers) | Bovine | 500 μg/kg | Fat | Further provisions in Council Directive 94/29/EC are to be observed |
50 μg/kg | Kidney | ||||
50 μg/kg | Milk | ||||
Cyfluthrin | Cyfluthrin (sum of isomers) | Bovine | 10 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
10 μg/kg | Liver | ||||
10 μg/kg | Kidney | ||||
20 μg/kg | Milk] ] | ||||
[F18 [F4Deltamethrin | Deltamethrin | All ruminants | 10 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
10 μg/kg | Liver | ||||
10 μg/kg | Kidney | ||||
20 μg/kg | Milk] | ||||
[F19Fin fish | 10 μg/kg | Muscle and skin in natural proportions] ] | |||
[F20Fenvalerate | Fenvalerate (sum of RR, SS, RS and SR isomers) | Bovine | 25 μg/kg | Muscle | |
250 μg/kg | Fat | ||||
25 μg/kg | Liver | ||||
25 μg/kg | Kidney | ||||
40 μg/kg | Milk] | ||||
Flumethrin | Flumethrin (sum of trans-Z isomers) | Bovine | 10 μg/kg | Muscle | |
150 μg/kg | Fat | ||||
20 μg/kg | Liver | ||||
10 μg/kg | Kidney | ||||
30 μg/kg | Milk | ||||
[F21 | Ovine | 10 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption | |
150 μg/kg | Fat | ||||
20 μg/kg | Liver | ||||
10 μg/kg | Kidney | ] | |||
[F17Permethrin | Permethrin (sum of isomers) | Bovine | 50 μg/kg | Muscle | |
500 μg/kg | Fat | ||||
50 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
50 μg/kg | Milk a | ] | |||
[F22Cypermethrin | Cypermethrin (sum of isomers) | Salmonidae | 50 μg/kg | Muscle and skin in natural proportions | ] |
[F4All ruminants | 20 μg/kg | Muscle | |||
200 μg/kg | Fat | ||||
20 μg/kg | Liver | ||||
20 μg/kg | Kidney | ||||
20 μg/kg | Milk a | ] | |||
[F23Alphacypermethrin | Cypermethrin (sum of isomers) | Bovine, ovine | 20 μg/kg | Muscle | |
200 μg/kg | Fat | ||||
20 μg/kg | Liver | ||||
20 μg/kg | Kidney | ||||
20 μg/kg | Milk] a |
Textual Amendments
F17 Inserted by Commission Regulation (EC) No 61/2003 of 15 January 2003 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F18 Inserted by Commission Regulation (EC) No 1815/2001 of 14 September 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F19 Inserted by Commission Regulation (EC) No 2162/2001 of 7 November 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F20 Inserted by Commission Regulation (EC) No 1805/2006 of 7 December 2006 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards thiamphenicol, fenvalerate and meloxicam (Text with EEA relevance).
F21 Inserted by Commission Regulation (EC) No 2391/2000 of 27 October 2000 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F22 Inserted by Commission Regulation (EC) No 1029/2003 of 16 June 2003 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F23 Inserted by Commission Regulation (EC) No 2011/2003 of 14 November 2003 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
a [F25Not for use in animals from which milk is produced for human consumption.] ] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
[F26Diflubenzuron | Diflubenzuron | Salmonidae | 1 000 μg/kg | Muscle and skin in natural proportions | ] |
[F25Fluazuron | Fluazuron | Bovine a | 200 μg/kg | Muscle | |
7 000 μg/kg | Fat | ||||
500 μg/kg | Liver | ||||
500 μg/kg | Kidney] | ||||
Teflubenzuron | Teflubenzuron | Salmonidae | 500 μg/kg | Muscle and skin in natural proportions |
Textual Amendments
F25 Inserted by Commission Regulation (EC) No 1451/2006 of 29 September 2006 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards fluazuron, sodium nitrite and peforelin (Text with EEA relevance).
F26 Inserted by Commission Regulation (EC) No 2593/1999 of 8 December 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Textual Amendments
F24 Inserted by Commission Regulation (EC) No 1931/1999 of 9 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Dicyclanil | Sum of dicyclanil and 2, 4, 6-triamino-pyrimidine-5-carbonitrile | Ovine | 200 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
[F28150 μg/kg] | Fat | ||||
400 μg/kg | Liver | ||||
400 μg/kg | Kidney] |
Textual Amendments
F28 Substituted by Commission Regulation (EC) No 2391/2000 of 27 October 2000 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Textual Amendments
F27 Inserted by Commission Regulation (EC) No 1960/2000 of 15 September 2000 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Cyromazine | Cyromazine | Ovine | 300 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
300 μg/kg | Fat | ||||
300 μg/kg | Liver | ||||
300 μg/kg | Kidney] |
a [F29Not for use in animals from which milk is produced for human consumption.] | |||||
Phramacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Abamectin | Avermectin B1a | Bovine | 10 μg/kg | Fat | |
20 μg/kg | Liver | ||||
[F12 | Ovine | 20 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption | |
50 μg/kg | Fat | ||||
25 μg/kg | Liver | ||||
20 μg/kg | Kidney | ] | |||
[F30Doramectin | Doramectin | All mammalian food producing species a | 40 μg/kg | Muscle | |
150 μg/kg | Fat | ||||
100 μg/kg | Liver | ||||
60 μg/kg | Kidney] | ||||
[F31Emamectin | Emamectin B1a | Fin fish | 100 μg/kg | Muscle and skin in natural proportions | ] |
Eprinomectin | Eprinomectin B1a | Bovine | [F3250 μg/kg] | Muscle | |
[F32250 μg/kg] | Fat | ||||
[F321 500 μg/kg] | Liver | ||||
[F32300 μg/kg] | Kidney | ||||
[F3220 μg/kg] | Milk | ||||
Ivermectin | 22, 23-Dihydro-avermectin B1a | Bovine | 40 μg/kg | Fat | |
100 μg/kg | Liver | ||||
Porcine, ovine, equidae | 20 μg/kg | Fat | |||
15 μg/kg | Liver | ||||
Deer, including reindeer | 20 μg/kg | Muscle | |||
100 μg/kg | Fat | ||||
50 μg/kg | Liver | ||||
20 μg/kg | Kidney | ||||
[F33 | All mammalian food-producing species a | 100 μg/kg | Fat | ||
100 μg/kg | Liver | ||||
30 μg/kg | Kidney | ] | |||
Moxidectin | Moxidectin | Bovine, ovine | 50 μg/kg | Muscle | |
500 μg/kg | Fat | ||||
100 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
[F34 | Bovine | 40 μg/kg | Milk | ] | |
[F11 | Equidae | 50 μg/kg | Muscle | ||
500 μg/kg | Fat | ||||
100 μg/kg | Liver | ||||
50 μg/kg | Kidney | ] | |||
[F35 | Ovine | 40 μg/kg | Milk | ] |
Textual Amendments
F29 Inserted by Commission Regulation (EC) No 869/2005 of 8 June 2005 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards ivermectin and carprofen (Text with EEA relevance).
F30 Substituted by Commission Regulation (EC) No 1831/2006 of 13 December 2006 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards Doramectin (Text with EEA relevance).
F31 Substituted by Commission Regulation (EC) No 1490/2003 of 25 August 2003 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F32 Substituted by Commission Regulation (EC) No 1943/1999 of 10 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F33 Substituted by Commission Regulation (EC) No 869/2005 of 8 June 2005 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards ivermectin and carprofen (Text with EEA relevance).
F34 Inserted by Commission Regulation (EC) No 1553/2001 of 30 July 2001 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F35 Inserted by Commission Regulation (EC) No 75/2005 of 18 January 2005 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards moxidectin, linear alkyl benzene sulphonic acids with alkyl chain lengths ranging from C9 to C13, containing less than 2,5 % of chains longer than C13 and Acetylisovaleryltylosin (Text with EEA relevance).
a [F36Not for use in animals from which milk is produced for human consumption. | |||||
b For porcine species this MRL relates to ‘ skin and fat in natural proportions ’ . | |||||
c Not for use in animals from which eggs are produced for human consumption.] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Toltrazuril | Toltrazuril sulfone | Chicken | 100 μg/kg | Muscle | Not for use in animals from which eggs are produced for human consumption |
200 μg/kg | Skin and fat | ||||
600 μg/kg | Liver | ||||
400 μg/kg | Kidney | ||||
Turkey | 100 μg/kg | Muscle | |||
200 μg/kg | Skin and fat | ||||
600 μg/kg | Liver | ||||
400 μg/kg | Kidney | ||||
[F37 | Porcine | 100 μg/kg | Muscle | ||
150 μg/kg | Skin and fat | ||||
500 μg/kg | Liver | ||||
250 μg/kg | Kidney | ] | |||
[F36 | All mammalian food producing species a | 100 μg/kg | Muscle | ||
150 μg/kg | Fat b | ||||
500 μg/kg | Liver | ||||
250 μg/kg | Kidney | ||||
Poultry c | 100 μg/kg | Muscle | |||
200 μg/kg | Skin + fat | ||||
600 μg/kg | Liver | ||||
400 μg/kg | Kidney | ] |
Textual Amendments
F36 Inserted by Commission Regulation (EC) No 205/2006 of 6 February 2006 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards toltrazuril, diethylene glycol monoethyl ether and polyoxyethylene sorbitan monooleate (Text with EEA relevance).
F37 Inserted by Commission Regulation (EC) No 2908/2000 of 29 December 2000 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Halofuginone | Halofuginone | Bovine | 10 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
25 μg/kg | Fat | ||||
30 μg/kg | Liver | ||||
30 μg/kg | Kidney] |
a [F38Not for use in ovine from which milk is produced for human consumption.] ] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Imidocarb | Imidocarb | Bovine | 300 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
2 000 μg/kg | Liver | ||||
1 500 μg/kg | Kidney | ||||
50 μg/kg | Milk | ||||
[F38Ovine a | 300 μg/kg | Muscle | |||
50 μg/kg | Fat | ||||
2 000 μg/kg | Liver | ||||
1 500 μg/kg | Kidney | ] |
Textual Amendments
F38 Inserted by Commission Regulation (EC) No 2145/2003 of 8 December 2003 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
[F6Lasalocid | Lasalocid A | Poultry | 20 μg/kg | Muscle | |
100 μg/kg | Skin + fat | ||||
100 μg/kg | Liver | ||||
50 μg/kg | Kidney] ] ] |
Textual Amendments
F39 Inserted by Commission Regulation (EC) No 712/2005 of 11 May 2005 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards lasalocid and ammonium and sodium salts of bituminosulfonates (Text with EEA relevance).
Textual Amendments
Y Diweddaraf sydd Ar Gael (diwygiedig):Y fersiwn ddiweddaraf sydd ar gael o’r ddeddfwriaeth yn cynnwys newidiadau a wnaed gan ddeddfwriaeth ddilynol ac wedi eu gweithredu gan ein tîm golygyddol. Gellir gweld y newidiadau nad ydym wedi eu gweithredu i’r testun eto yn yr ardal ‘Newidiadau i Ddeddfwriaeth’.
Gwreiddiol (Fel y’i mabwysiadwyd gan yr UE): Mae'r wreiddiol version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Pwynt Penodol mewn Amser: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Rhychwant ddaearyddol: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Dangos Llinell Amser Newidiadau: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Gallwch wneud defnydd o ddogfennau atodol hanfodol a gwybodaeth ar gyfer yr eitem ddeddfwriaeth o’r tab hwn. Yn ddibynnol ar yr eitem ddeddfwriaeth sydd i’w gweld, gallai hyn gynnwys:
Mae’r llinell amser yma yn dangos y fersiynau gwahanol a gymerwyd o EUR-Lex yn ogystal ag unrhyw fersiynau dilynol a grëwyd ar ôl y diwrnod ymadael o ganlyniad i newidiadau a wnaed gan ddeddfwriaeth y Deyrnas Unedig.
Cymerir dyddiadau fersiynau’r UE o ddyddiadau’r dogfennau ar EUR-Lex ac efallai na fyddant yn cyfateb â’r adeg pan ddaeth y newidiadau i rym ar gyfer y ddogfen.
Ar gyfer unrhyw fersiynau a grëwyd ar ôl y diwrnod ymadael o ganlyniad i newidiadau a wnaed gan ddeddfwriaeth y Deyrnas Unedig, bydd y dyddiad yn cyd-fynd â’r dyddiad cynharaf y daeth y newid (e.e. ychwanegiad, diddymiad neu gyfnewidiad) a weithredwyd i rym. Am ragor o wybodaeth gweler ein canllaw i ddeddfwriaeth ddiwygiedig ar Ddeall Deddfwriaeth.
Defnyddiwch y ddewislen hon i agor dogfennau hanfodol sy’n cyd-fynd â’r ddeddfwriaeth a gwybodaeth am yr eitem hon o ddeddfwriaeth. Gan ddibynnu ar yr eitem o ddeddfwriaeth sy’n cael ei gweld gall hyn gynnwys:
liciwch ‘Gweld Mwy’ neu ddewis ‘Rhagor o Adnoddau’ am wybodaeth ychwanegol gan gynnwys